hCG Supplementation in Frozen-Thawed Embryo Transfer Cycle

The Benefit of Human Chorionic Gonadotropin (hCG) Supplementation Throughout the Secretory Phase of Frozen-Thawed Embryo Transfer Cycles

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00398229

Enrollment

300

Registered

2006-11-10

Start date

2006-11-30

Completion date

2008-05-31

Last updated

2009-01-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fertility Agents, Female

Keywords

In-Vitro Fertilization, human chorionic gonadotropin, frozen-thawed embryo transfer, implantation rate

Brief summary

The implantation rate after frozen-thawed embryo transfer cycles depends mostly on the receptivity of the endometrium and the embryo quality.The effects of human chorionic gonadotropins (hCG) on the endometrium have been investigated for several years. hCG was shown to up-regulate gene expression during the differentiation of human endometrial stromal cells into decidua. The aim of our study was to assess the benefit of hCG supplementation throughout the secretory phase of artificial frozen-thawed embryo transfer cycles.

Interventions

DRUGs.c. human chorionic gonadotropin (Ovitrelle)

S.C. Ovitrelle 250 mcg once

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 45 Years

Healthy volunteers

Inclusion criteria

* all women on frozen-thawed embryo-transfer cycle

Exclusion criteria

* any allergy to injection of human chorionic gonadotropin before

Design outcomes

Primary

Measure	Time frame
implantation rate	4 weeks
pregnancy rate	4 weeks

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026